Eurofins CDMO Expands Spray Drying Capabilities
11 Janvier 2022 - 3:30PM
Business Wire
Eurofins CDMO announces the expansion of existing Spray Dry
Development & Production Services in North America. The
Canadian facility, located in Mississauga, ON, has expanded its
cGMP Spray Drying capabilities with the addition of a GEA Mobile
Minor spray drying system and dedicated 500 sq. ft. clean room.
With this expansion, Eurofins CDMO can further complement a
broad range of services specializing in solubility enhancement for
clinical development and small scale commercial programs. Its
process capabilities include solvent or aqueous systems, highly
potent compounds, API and Drug Product development and
manufacturing, solid state characterization, oral solid and
inhalation dosage forms.
The expansion of Spray Drying at Eurofins CDMO provides
continued support of clinical development programs where
formulation enabling is required for poorly soluble compounds.
The new Spray Dry system enables manufacturing of solid
dispersions at multi-kilo scale in support of a wide range of
finished dosage forms for early clinical through to niche
commercial programs.
About Eurofins CDMO
Eurofins CDMO is a leading global Contract Development and
Manufacturing Organization that provides clients with Active
Pharmaceutical Ingredients (API’s) / Drug Substance and Drug
Product development for small molecules and biologicals. Its
service offering encompasses Drug Substance/API Development, Solid
State Research and Development, Pre-formulation, Formulation and
Development, Analytical Development, GMP Manufacturing and Clinical
Packaging and Logistics. Operating with facilities in Europe, North
America and India, Eurofins CDMO is accredited through the FDA,
EMA, ANSM, ANSES, FAMHP, PMDA, and Health Canada.
About Eurofins – the global leader in bio-analysis
Eurofins (Paris:ERF) is Testing for Life. Eurofins is the global
leader in food, environment, pharmaceutical and cosmetic product
testing and in agroscience Contract Research services. It is also
one of the market leaders in testing and laboratory services for
genomics, discovery pharmacology, forensics, BioPharma Contract
Development and Manufacturing, advanced material sciences and has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a network of 900 laboratories in over
50 countries, Eurofins’ companies offer a portfolio of over 200,000
analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220111005140/en/
Delphine Gricourt ir@eurofins.com For more information:
www.eurofins.com/cdmo
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024